Evopoint Biosciences Co., Ltd. (SHA:688837)
China · Delayed Price · Currency is CNY 49.40
+5.79 (13.28%)
Sep 30, 2026, 3:00 PM CST
Evopoint Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Operating Revenue | 1,103 | 927.19 | - | - | 19.5 |
Other Revenue | 8.06 | 8.06 | - | - | - |
| 1,111 | 935.24 | - | - | 19.5 | |
Revenue Growth | - | - | - | - | - |
Gross Profit | 1,111 | 935.24 | - | - | 19.5 |
Selling, General & Admin | 97.56 | 215.34 | 74.64 | 82.48 | 77.89 |
Research & Development | 570.62 | 509 | 387.44 | 367.61 | 463.92 |
Other Operating Expenses | -15.26 | 0.79 | 0.02 | 0.07 | 0.25 |
Operating Expenses | 652.92 | 725.13 | 462.1 | 450.16 | 542.06 |
Operating Income | 458.11 | 210.11 | -462.1 | -450.16 | -522.56 |
Interest Expense | -23.87 | -23.87 | -15.89 | -7.78 | -2.95 |
Interest & Investment Income | 7.12 | 6.96 | 7.87 | 4.17 | 39.83 |
Currency Exchange Gain (Loss) | -5.2 | -5.2 | 0.28 | 0.26 | 6.04 |
Other Non Operating Income (Expenses) | -9.76 | -0.08 | -0.05 | -0.08 | -0.05 |
EBT Excluding Unusual Items | 426.41 | 187.93 | -469.9 | -453.59 | -479.68 |
Gain (Loss) on Sale of Investments | 141.34 | 156.73 | 59.38 | 18.23 | 10.5 |
Gain (Loss) on Sale of Assets | - | - | 0 | 0.05 | -0.1 |
Other Unusual Items | -49.38 | -49.38 | 24.51 | 8.42 | 6.65 |
Pretax Income | 518.37 | 295.27 | -386 | -426.89 | -462.63 |
Income Tax Expense | 109.86 | 92.72 | - | - | - |
Net Income | 408.51 | 202.56 | -386 | -426.89 | -462.63 |
Net Income to Common | 408.51 | 202.56 | -386 | -426.89 | -462.63 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 370 | 368 | 368 | 342 | 326 |
Shares Outstanding (Diluted) | 370 | 368 | 368 | 342 | 326 |
Shares Change | - | 0.18% | 7.65% | 4.82% | - |
EPS (Basic) | 1.11 | 0.55 | -1.05 | -1.25 | -1.42 |
EPS (Diluted) | 1.11 | 0.55 | -1.05 | -1.25 | -1.42 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | 211.72 | 115.66 | -399.57 | -460.68 | -580.75 |
Free Cash Flow Per Share | 0.57 | 0.31 | -1.09 | -1.35 | -1.78 |
Gross Margin | 100.00% | 100.00% | - | - | 100.00% |
Operating Margin | 41.23% | 22.47% | - | - | -2679.80% |
Profit Margin | 36.77% | 21.66% | - | - | -2372.47% |
Free Cash Flow Margin | 19.06% | 12.37% | - | - | -2978.22% |
EBITDA | 490.39 | 242.5 | -443.53 | -440.51 | -515.57 |
EBITDA Margin | 44.14% | 25.93% | - | - | - |
D&A For EBITDA | 32.28 | 32.39 | 18.57 | 9.65 | 6.99 |
EBIT | 458.11 | 210.11 | -462.1 | -450.16 | -522.56 |
EBIT Margin | 41.23% | 22.47% | - | - | - |
Effective Tax Rate | 21.19% | 31.40% | - | - | - |